As researchers and clinicians converge on New Orleans for the annual meeting of the American Society of Hematology (ASH) this weekend, one thing is clear: There will be a bumper crop of data on drugs for the treatment of chronic lymphocytic leukemia (CLL). The society itself is putting on a press briefing on “the changing landscape of CLL.”